[Claims]

[Claim 1]

A pharmaceutical composition containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, the pharmaceutical composition comprising:

~~5~~7 to 12% by mass of the luliconazole or the pharmaceutically acceptable salt thereof relative to a total mass of the pharmaceutical composition;

a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer;

ethanol;

benzyl alcohol;

lactic acid;

propylene carbonate; and

3 to 10 % by mass of acetone relative to a total mass of the pharmaceutical composition~~acetone~~.

[Claim 2]

The pharmaceutical composition according to claim 1, wherein the luliconazole or the pharmaceutically acceptable salt thereof is contained at 7 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 3]

The pharmaceutical composition according to claim 1 or 2, wherein the polyethylene glycol having an average molecular weight of 380 to 420 represented by the formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer is contained at 5 to 40% by mass relative to the total mass of the pharmaceutical composition.

[Claim 4]

The pharmaceutical composition according to any one of claims 1 to 3, wherein the ethanol is contained at 20 to 70% by mass relative to the total mass of the pharmaceutical composition.

[Claim 5]

The pharmaceutical composition according to claim 4, wherein the ethanol is contained at 30% by mass or more and less than 50% by mass relative to the total mass

of the pharmaceutical composition.

[Claim 6]

The pharmaceutical composition according to any one of claims 1 to 5, wherein the benzyl alcohol is contained at 0.01 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 7]

The pharmaceutical composition according to any one of claims 1 to 6, wherein the lactic acid is contained at 1 to 10% by mass relative to the total mass of the pharmaceutical composition.

[Claim 8]

The pharmaceutical composition according to any one of claims 1 to 7, wherein the propylene carbonate is contained at 1 to 15% by mass relative to the total mass of the pharmaceutical composition.

[Claim 9]

The pharmaceutical composition according to any one of claims 1 to 8, further comprising isopropyl myristate ~~wherein the acetone is contained at 1 to 25% by mass relative to the total mass of the pharmaceutical composition~~.

[Claim 10]

The pharmaceutical composition according to claim 9 ~~any one of claims 1 to 9~~, wherein the isopropyl myristate is contained at 1 to 10% by mass relative to the total mass of the pharmaceutical composition ~~further comprising isopropyl myristate~~.

[Claim 11]

The pharmaceutical composition according to any one of claims 1 to 10~~claim 10~~, further comprising a film forming agent ~~wherein the isopropyl myristate is contained at 1 to 10% by mass relative to the total mass of the pharmaceutical composition~~.

[Claim 12]

The pharmaceutical composition according to claim 11~~any one of claims 1 to 11~~, wherein the film forming agent contains a mixture of an acrylic resin alkanolamine and ethanol, or a mixture of (alkyl acrylate/diacetone acrylamide) copolymer AMP and ethanol ~~further comprising a film forming agent~~.

[Claim 13]

The pharmaceutical composition according to claim 11 or 12, wherein the film forming agent is contained at 0.01 to 4% by mass relative to the total mass of the pharmaceutical composition ~~contains a mixture of an acrylic resin alkanolamine and ethanol, or a~~

~~mixture of (alkyl acrylate/diacetone acrylamide) copolymer AMP and ethanol~~.

[Claim 14]

The pharmaceutical composition according to any one of claims 1 to 13~~claim 12 or 13~~, further comprising N-methyl-2-pyrrolidone ~~wherein the film-forming agent is contained at 0.01 to 4% by mass relative to the total mass of the pharmaceutical composition~~.

[Claim 15]

The pharmaceutical composition according to any one of claims 1 to ~~14~~13, which is free of N-methyl-2-pyrrolidone ~~further comprising N-methyl-2-pyrrolidone~~.

[Claim 16]

Use of ~~T~~the pharmaceutical composition according to any one of claims 1 to ~~16~~15, in the manufacture of a medicament for the treatment~~ing~~ or preventio~~n~~g of onychomycosis.

[Claim 17]

The ~~pharmaceutical composition~~use according to claim~~s 1 to~~ 16, wherein the onychomycosis is distal subungual onychomycosis ~~for treating or preventing onychomycosis~~.

[Claim 18]

The ~~pharmaceutical composition~~use according to claim 16 or 17, wherein the onychomycosis is an infection of toenails ~~distal subungual onychomycosis~~.

[Claim 19]

The ~~pharmaceutical composition~~use according to claim 16 or 17~~17 or 18~~, wherein the onychomycosis is an infection of fingernails ~~toenails~~.

[Claim 20]

The ~~pharmaceutical composition~~use according to any one of claims 16 to 19 ~~claim 17 or 18~~, wherein the pharmaceutical composition is an external medicine ~~onychomycosis is an infection of fingernails.~~

[Claim 21]

The ~~pharmaceutical composition~~use according to claim 20~~any one of claims 1 to 20~~, wherein the pharmaceutical composition is applied to an affected area once a day ~~which is an external medicine.~~

[Claim 22]

A method of preparing the pharmaceutical composition according to any one of claims 1 to 15,

the method comprising mixing the luliconazole or the pharmaceutically acceptable salt thereof with the polyethylene glycol having an average molecular weight of 380 to 420 represented by the formula $HOCH_2(CH_2OCH_2)_nCH_2OH$ where n is an integer, the ethanol, the benzyl alcohol, the lactic acid, the propylene carbonate, and the acetone ~~The pharmaceutical composition according to claim 21, which is applied to an affected area once a day~~.

[Claim 23]

The pharmaceutical composition according to any one of claims 1 to 15 for use in the treatment or prevention of onychomycosis~~A method of preparing the pharmaceutical composition according to any one of claims 1 to 22, the method comprising mixing the luliconazole or the pharmaceutically acceptable salt thereof with the polyethylene glycol having an average molecular weight of 380 to 420 represented by the formula HOCH2(CH2OCH2)nCH2OH where n is an integer, the ethanol, the benzyl alcohol, the lactic acid, the propylene carbonate, and the acetone~~.